MayBio Secures Tens of Millions in Angel Funding Led by Danlu Capital to Advance Human-Derived Collagen Platform

BeijingMAYBIOPharmaceuticalsBiologyis an innovative enterprise dedicated to the research and development, production, and sales of medical aesthetic products.CEO Mei Jinzhuo has many years of experience in pharmaceutical sales and medical aesthetics operations. The core R&D team consists of members from Peking University, Sichuan University, and other“OverseasHigh-End Talent Introduction Program” ofcomposed of scholars. Unlike collagen derived from animals or recombinant expression, MAYBIO employs“"Human-derived mesenchymal stem cells"as an expression vector, achieving humanized compositeCollagenIndustryChemicalSafe and efficient production, with1500㎡GMP Sterile Gel Filling Workshop, 80Annual production capacity of 10,000 units of collagen gel.

At the recently heldAt an industry salon themed “Collagen,”MAYBIODevelopmentCo., Ltd.Invited senior medical aesthetics industry professionals from Bloomage Biotech, Meivos, and well-known firms such as SequoiaInvestment Institutionsand well-knownMedical Aesthetics Expert. The salon featured in-depth discussions on the technological evolution and development of human-derived collagen, as well as its applications and industrialization in medical aesthetics and regenerative medicine.Dr. Liang Shuang, General Manager of Investment at Bloomage Biotechnology, stated that “collagen aligns with the development needs of the medical aesthetics industry and clinical applications.” Professor Bi Hongsen, Medical Director of the Department of Plastic and Reconstructive Surgery at Peking University Third Hospital, introducedRejuvenation for High-Quality Fillers and Regenerative Materialsurgent need。Qin Jinping, Founder of MedverseMr.We are highly optimistic about the application prospects of collagen products in the field of aesthetic medicine and plastic surgery, and believe that MAYBIO will be able to excel in this sectorGreat Potential, currently, MAYBIO has secured tens of millions in angel-round investment led by Redhill Capital.